Pharmacodynamic biomarker-guided metabolic collapse of IDH-mutant glioma
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2110624
- Recipient
-
Mayo Clinic UEI Y2K4F9RPRRG7
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $795,000
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- Rochester, MN 55905, USA
Award details come from USAspending.gov.
About this award
Mayo Clinic will receive $795,000 from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) to conduct the project "PHARMACODYNAMIC BIOMARKER-GUIDED METABOLIC COLLAPSE OF IDH-MUTANT GLIOMA" from September 2021 through September 2024. This Project Grant aims to develop medical solutions for the battlefield by investigating pharmacodynamic biomarkers to guide targeted metabolic therapies for the treatment of isocitrate dehydrogenase (IDH) mutant glioma, a type of brain tumor. The funding will support Mayo Clinic's efforts to transform healthcare through innovative biomedical research with the potential to benefit both military service members and the public.
Quick answers
Who received award W81XWH2110624?
W81XWH2110624 was awarded to Mayo Clinic by Medical Command (Department of the Army) on September 15, 2021.
How much is award W81XWH2110624 worth?
$795,000 has been obligated on W81XWH2110624.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award